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Abstract
Pyrazinamide (PZA) is an important first-line anti-tuberculosis drug. But PZA susceptibility test is challenging because PZA
activity is optimal only in an acid environment that inhibits the growth of M. tuberculosis. For current phenotypic methods,
inconsistent results between different labs have been reported. Direct sequencing of pncA gene is being considered as an
accurate predictor for PZA susceptibility, but this approach needs expensive sequencers and a mutation database to report
the results. An in-vitro synthesized Pyrazinamidase (PZase) assay was developed based on PCR amplification of pncA gene
and an in vitro wheat germ system to express the pncA gene into PZase. The activity of the synthesized PZase was used as
an indicator for PZA susceptibility. Fifty-one clinical isolates were tested along with pncA sequencing and the BACTEC MGIT
960 methods. The in-vitro synthesized PZase assay was able to detect PZA susceptibility of M. tuberculosis within 24 h
through observing the color difference either by a spectrometer or naked eyes. This method showed agreements of 100%
(33/33) and 88% (14/16) with the pncA sequencing method, and agreements of 96% (27/28) and 65% (15/23) with the
BACTEC MGIT 960 method, for susceptible and resistant strains, respectively. The novel in-vitro synthesized PZase assay has
significant advantages over current methods, such as its fast speed, simplicity, no need for expensive equipment, and the
potentials of being a direct test, predicting resistance level and easy reading results by naked eyes. After confirmation by
more clinical tests, this method may provide a radical change to the current PZA susceptibility assays.
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Introduction
The emergence of drug-resistant strains is one of the main
causes for the current spread of Tuberculosis (TB) and it is
clinically important to do drug susceptibility testing for better
control of TB [1,2]. Pyrazinamide (PZA) is an important first-line
anti-tuberculosis drug used in combination with isoniazid,
rifampicin and ethambutol in the short-course treatment regimens
recommended by the WHO [3]. While the procedures for
susceptibility testing of the first-line and second-line drugs have
been well standardized in both liquid and solid media, the PZA
susceptibility test is challenging because the bactericidal activity of
PZA is optimal only in an acid environment (pH 5.5–5.6) that
inhibits the growth of M. tuberculosis isolates [4,5].
Many phenotypic methods [6,7,8,9] were developed to perform
the assay at higher pH (around 6.0) and increased PZA
concentrations, which are far beyond the active PZA concentra-
tion in vivo. Among them, the radiometric assay (BACTEC 460TB)
using pH 6.0 and PZA concentration of 100ug/mL was
considered as most reliable and the currently recommended assay
(Clinical Laboratory Standard Institute, M24-A2). However, even
for this reference method, inconsistent results between different
labs have been reported [10,11]. Previous studies found that the
radiometric assay can lead to inconclusive results up to 3.5% of the
strains [12], falsely resistant results for at least 0.8% of the strains
[13], and falsely susceptible results for some strains [14].
Direct sequencing of pncA gene is being considered as a more
reliable and accurate method to predict PZA susceptibility [14,15].
Since pncA gene (GenBank accession number U59967), encoding
PZase, was cloned in 1996 [16], a lot of research confirmed that
mutations in pncA could result in lost or reduced PZase activity,
and such mutations were proven to be the primary mechanism of
PZA resistance in M. tuberculosis [17,18,19]. The fact that over 90%
of PZA-resistant M. tuberculosis isolates carry mutations in the
coding region of pncA, makes it possible to test PZA susceptibility
through monitoring mutations in the pncA gene [17,20,21].
Because PZA resistance mutations are highly diverse and found
throughout the entire pncA gene, direct sequencing of PCR
products and DNA microarrays [22] were used frequently.
However, these methods are not commonly available due to
costly apparatus, and could only be used for predication or need a
pre-known database to link the mutation sites with the sus-
ceptibility results. For new mutation sites, further confirmation by
phenotypic testing is needed.
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27654A hybrid genetic and phenotypic method based on PCR and in-
vitro cell free expression systems to do rapid PZase assay might be
an ideal choice for PZA susceptibility test [23]. Due to the strong
red color of the rabbit reticulocyte lysate used in the previous
study, a tedious treatment was needed to remove the red
hemoglobin to avoid the interference with PZase assay. More
troublesome, two pairs of PCR primers were needed in order to
cover all possible mutations in the pncA genes, which mean double
PCR and in-vitro expression for one sample and therefore,
significant increase of cost and work load. All these issues limited
further applications of this method.
In this study, we developed a simple colorimetric method to
enable rapid PZA susceptibility testing based on PCR amplifica-
tion of pncA gene and an in-vitro wheat germ system. We also
demonstrated, for the first time, that this method may have the
potential of being a direct test for sputum specimens, therefore,
bypassing the lengthy cultivation of tubercle bacilli.
Results
Amplification of pncA gene by primers with or without
59-UTR sequence
In order for PCR products to cover possible mutations on the
whole pncA gene, PCR primers were designed from the upstream
and the downstream regions of pncA gene on M. tuberculosis genome
(Fig. 1A and 1B). A T7 promoter was attached with the forward
primers in order for the wheat germ system to express protein
directly from PCR products. To shorten in-vitro expression time,
59-untranslated regulatory regions (59UTR) were also considered
since some 59UTR sequences could enhance protein expression in
wheat germ system [24]. After optimization, two pairs of primers
shown in the supplementary Table S1 were synthesized and used
to amplify pncA gene. As shown in Fig. 1C, both primer pairs could
effectively amplify pncA gene of M. tuberculosis H37Ra and M. bovis
BCG. Similar electrophoresis results were also obtained for pncA
genes amplified from all the clinical samples tested (data not
shown).
Optimization of primers and incubation time for in-vitro
synthesis of PZase
Fig. 2A and 2B show a comparison of PZase activities of M.
tuberculosis H37Ra and M. bovis BCG obtained by using the primer
pairs with or without the 59UTR sequence, respectively. Using F-5
and R-1 as the primers, the PZase activity obtained with the pncA
gene amplified from M. tuberculosis H37Ra was about double (tube
3, Fig. 2B) to that using F-NO5 and R-1 as the primers (tube 1,
Fig. 2B). While minimum PZase activity (no red color) was
observed with the pncA gene amplified from M. bovis BCG using
either primer pairs (tubes 2 and 4, Fig. 2B). Thus, the in-vitro PZase
synthesis was more efficient using the PCR products that contain
the 59UTR sequence. Fig. 2C shows that the PZase activity of the
lysate containing the M. tuberculosis H37Ra PCR product increased
continuously in a time-dependent manner, which was clearly due
to that more PZase was synthesized in longer reaction time. In
contrast, almost no PZase activity was observed in the lysates
containing the M. bovis BCG PCR product even after 20 hours of
incubation. An incubation time of 10 hours was chosen in terms of
speed and efficiency. In the following experiments, primers F-5
and R-1 were used as the PCR primers and the expression time
was set at 10 hours.
PZA susceptibility testing of M. tuberculosis clinical
samples by the in-vitro synthesized PZase assay
PZA susceptibility of 51 clinical isolates was examined. In order
to know the reproducibility and obtain the cut-off threshold to
judge PZA susceptibility, the 51 isolates were divided into three
batches and tested together with M. tuberculosis H37Ra and M. bovis
BCG. In each batch, each sample was tested twice; M. tuberculosis
H37Ra and M. bovis BCG were tested in three repeats. The
samples were processed and the optical density (OD) ratios of the
samples including M. tuberculosis H37Ra and M. bovis BCG were
calculated by dividing the OD value of each well to the mean OD
value from three replicate M. tuberculosis H37Ra tubes in the same
batch. Because any mutations resulting reduced PZase activity
would generate PZA resistance, a clinical sample was scored as
resistant if the mean OD ratio from its two replicate tubes was
lower than a cutoff threshold, which was set at the mean minus
three SDs of the OD ratios of all the nine tubes of M. tuberculosis
H37Ra in the three batches.
Fig. 3A and 3B show OD ratios relative to M. tuberculosis H37Ra
and the pictures of the in-vitro synthesized PZase activities of all the
samples, respectively. Among all the samples tested, 16 samples
exhibited PZase activities with their OD ratios relative to M.
tuberculosis H37Ra lower than the cutoff. These 16 samples were
considered as PZA resistant. The remaining 35 samples were
considered as PZA susceptible with their OD ratios relative to M.
Figure 1. Schematic presentation of the primer positions without (A) and with 59UTR sequence (B), as well as gel electrophoresis
image of the PCR products (C). Lane M, markers; Lane 1, M. tuberculosis H37Ra template with primers F-NO5 and R-1; Lane 2, M. bovis BCG
template with primers F-NO5 and R-1; Lane 3, M. tuberculosis H37Ra template with primers F-5 and R-1; Lane 4, M. bovis BCG template with primers F-
5 and R-1. HS: hybridization sequence complement to genomic DNA of M. tuberculosis.
doi:10.1371/journal.pone.0027654.g001
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seen that the red color differences between PZA susceptible and
resistant strains were so obvious that they could be easily
discriminated by naked-eyes.
Sputum specimens with positive smear for AFB were also tested
and only one typical result was shown in Fig. 3. Based on the Blast
results, the primer sequences used in this study were quite specific
to the genome of M. tuberculosis, and had the possibility for direct
sputum tests. Generally we found that the success of this method
for sputum specimens depended on the PCR results. Various PCR
results were obtained for different sputum specimens (data not
shown). We are still optimizing the DNA extraction process to
establish the level of sensitivity (required minimal number of bacilli
in the specimen).
DNA sequencing and BACTEC MGIT 960 results of clinical
isolates
The BACTEC results of the isolates and the sequencing results
of pncA genes from the 51 isolates and the sputum specimen are
presented in Table 1. Comparing these results with that of the in-
vitro synthesized PZase assay, 27 isolates were found susceptible by
the PZase assay (Fig. 4A) and the BACTEC test, and their pncA
sequences revealed no mutations or a silent mutation (No. 17).
These 27 samples were identified as PZA susceptible by all the
three methods. 13 isolates were found resistant by the PZase assay
and the BACTEC test, and their pncA sequences revealed that they
have mutations, which were proved to lead to PZA resistance in
previous studies [17,18,20,21,25]. These 13 isolates were identified
as PZA resistant by all the three methods. In the remaining
isolates, six isolates were identified as PZA susceptible by the
PZase assay and the sequencing results, but PZA resistant by the
BACTEC test. Isolates No. 24 and 49 showed no loss of PZase
activity, which indicated PZA susceptible by the in-vitro PZase
assay. But the sequencing results revealed that No. 24 had a
mutation C(512)RA and No. 49 had two mutations C(458)RT
and C(474)RA. These site mutations were not reported before
whether lead to PZA resistance or not. The BACTEC test showed
these two isolates were resistant. For the two isolates (No. 26 and
44), whose DNA sequences could not been given due to the double
sequencing peaks (Figure S1), both the in-vitro PZase assay and the
BACTEC results showed PZA resistant. The sputum sample was
identified as PZA susceptible by the PZase assay and its
sequencing result.
As shown in Table 2, overall the in-vitro synthesized PZase
results showed agreements of 100% (33/33) and 88% (14/16) with
the pncA sequencing results, and agreements of 96% (27/28) and
65% (15/23) with the BACTEC MGIT 960 results, for susceptible
and resistant strains, respectively.
Discussion
The in-vitro PZase method showed very good agreements
(100% and 88% for susceptible and resistant strains, respectively)
in results with the pncA sequencing method, which demonstrated
that this method could be used to replace the pncA sequencing
method for accurate prediction of PZA susceptibility. Compared
with the direct sequencing method, the in-vitro synthesized PZase
assay provides a ‘yes/no’ PZA resistance by measuring if the
activity of the synthesized PZase is reduced related to that of the
wild type PZase, which is easy and cheap to perform in most
clinical labs without the need of expensive DNA sequencers.
Furthermore, the in-vitro PZase method has a significant
advantage that it does not need a pre-known mutation database
to report PZA susceptibility results. As shown in Table 1, this
method can give the susceptibility results for all the isolates,
including those with no available linkage of their pncA mutation
sites to resistance (isolates 24 and 49) and those that their pncA
sequences could not be obtained due to the double peak problem
(isolates 26 and 44, Figure S1). This advantage would be
especially important for clinical detections because new mutations
are expected to come out consistently for M. tuberculosis under
pressure of PZA.
Compared with the BACTEC MGIT 960 method, the in-vitro
PZase method is much faster (within 1 day) and safer for testing M.
tuberculosis isolates since it does not need to grow the cells, which
would eliminate the requirement of bio-safety level 3 lab for TB
diagnostics and remove one major stumbling block to expanding
lab capacity. Although these two methods showed good agreement
(96%) for PZA susceptible strains, only moderate agreement (65%)
for PZA resistant strains was obtained. The moderate agreement
may be partly due to that there are other PZA resistant
mechanisms other than mutations in pncA gene, but most probably
due to false resistance of the Bactec test with 100 ug/ml PZA
concentration as the breakpoint [18]. As shown in Table 1, there
were six isolates recognized as PZA resistant by the Bactec test, but
did not have any mutation in their gene sequences. As suggested
before [5,26], these six isolates might not be resistant to PZA at all.
Without considering these 6 isolates, the agreement would be 88%
(15/17) for PZA resistant strains.
Besides the advantages mentioned above, the in-vitro synthesized
PZase assay also provides some unique potentials which may
change the current PZA susceptibility assays. First, the incorpo-
ration of the 59-UTR sequence into the PCR products effectively
Figure 2. Activities of in-vitro synthesized PZase. Templates used
for the PCR were M. tuberculosis M. tuberculosis H37Ra (PZA susceptible;
white bar) and M. bovis BCG (PZA resistant; black bar). Optical density
(A) and colors (B) of PZase activities obtained by using PCR products
from M. tuberculosis H37Ra and M. bovis BCG with (F-5 as the forward
primer, tube 3: M. tuberculosis H37Ra; tube 4: M. bovis BCG) and without
(F-NO5 as the forward primer, tube 1: M. tuberculosis H37Ra; tube 2: M.
bovis BCG) the 59UTR sequence. Incubation time for in-vitro synthesis:
20 h. (C) Time course study of the synthesized PZase activities with F-5
as the forward primer and their corresponding colors (D). Tubes 1–4: M.
tuberculosis H37Ra, incubation for 0, 5, 10 and 20 hours, respectively.
Tubes 5–8: M. bovis BCG, incubation for 0, 5, 10 and 20 hours,
respectively.
doi:10.1371/journal.pone.0027654.g002
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the PZA resistant and susceptible samples in short time. As shown
in Fig. 3, the color difference was so obvious that it was possible to
use the color of M. tuberculosis H37Ra as the susceptible control
and the color of M. bovis BCG as the resistant control to aid naked
eyes to judge the susceptibility results. Secondly, initial studies
showed that this method could be used as a direct test for sputum
specimens, which would reduce the total turnaround time to 1–2
days without the time-costly isolation of M. tuberculosis. Finally, the
PZase activity of each sample may be used to predict its resistance
level, which may be more useful and more powerful evidence than
currently exists to support any culture-based breakpoints. One
recent study of recombinant mutated PZases showed that the level
of resistance was significantly associated with Pzase activity [27].
Figure 3. In-vitro synthesized PZase activities of clinical samples. A. OD ratios of samples relative to M. tuberculosis H37Ra. The samples with
their OD ratios relative to M. tuberculosis H37Ra below the cutoff were marked as black bars (PZA resistant). The samples with their OD ratios relative
to M. tuberculosis H37Ra above the cutoff were marked as gray bars (PZA susceptible). H: M. tuberculosis H37Ra, white bars; B: M. bovis BCG, hatched
bars.Sputum: sputum sample. Clinical isolates are labeled with their specimen No. B. Pictures of in-vitro synthesized PZase activities of all the clinical
samples. H: M. tuberculosis H37Ra; B: M. bovis BCG. Sputum: sputum sample. Clinical isolates are labeled with their specimen No.
doi:10.1371/journal.pone.0027654.g003
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isolates had different activities. From their corresponding mutation
sites revealed by the sequencing, it could find that the mutations
causing significant loss of PZase activity (such as isolates 9, 15, 35
and 45, with color close to that of M. bovis BCG) are those that
alter the catalytic residues comprising the active sites (D8, K96,
A134 and C138) and the iron-binding sites (D49, H51, H57 and
H71) revealed by the crystal structure of PZase [28]. Mutations
located farther away (such as isolates 24 and 49, with color close to
that of M. tuberculosis H37Ra) have less or no effect on PZase
activity. These results suggest that the PZase activity measured in
this method correctly reflected the changes of PZase due to
mutations, which change its ability to convert PZA, i.e., the
resistance level. However, all these potentials need further studies
to confirm.
To conclude, initial studies showed that the new PCR-based in-
vitro synthesized PZase assay had better performance than the
sequencing method in determining PZA susceptibility of M.
tuberculosis isolates and may have the potential to replace the
BACTEC MGIT 960, which is considered as a safer alternative to
the current golden standard radiometric BACTEC 460TB, for
PZA testing. This method showed some significant advantages
over current methods, such as its fast speed, simplicity and
potentials of being a direct test and easy reading results by naked
eyes. However, more clinical testing is needed to further evaluate
the method and more studies are needed to confirm its potentials.
If all these are going well, the in-vitro synthesized PZase assay may
provide a revolutionary PZA susceptibility assay for the clinical
labs and help to change the situation that most hospitals in
developing countries do not test PZA susceptibility.
Table 1. Results of PZA susceptibility of M. tuberculosis clinical samples tested by pncA sequencing, in-vitro synthesized PZase
assay and BACTEC MGIT 960 System.
No. of Strains
pncA sequencing
results and mutations
PZase
mutations
PZA susceptibility
by sequencing
PZA susceptibility by
the in-vitro PZase assay
PZA susceptibility
by BACTEC 960
1,2,3,4,5,6,7,8,
11, 14,16,
19,20,22,25
27,28,29,30,31
32, 36, 40,
42,43,46,
Sputum sample
d
WT
a WT
a SS S
10,12,18,34,38,50 WT
a WT
a SS R
9 T(202)RC Trp (86)RArg R ref. [20] R R
13 G (362)RC Arg(121)RPro R ref. [21] R R
15 C (169)RT His(57)RTyr R ref. [2] R R
17 C (234)RTW T
b SS S
21 A (29)RC Gln(10)RPro R ref. [18] R R
23 A insertion between
nt 192 and 193
Frame shift R R R
24 C(512)RA Ala(171)RGlu NA S R
26 ——
c ——
c NA R R
33 T(416)RG Val(139)RGly R ref. [20] R R
35 G(145)RT Asp(49)RTyr R R R
37 A(188)RC Asp(63)RAla R ref. [28] R S
39 T(416)RG Val(139)RGly R ref. [20] R R
41 T(199)RC Ser(67)RPro R ref. [20] R R
44 ——
c ——
c NA R R
45 C(169)RT His(57)RTyr R ref. [2] R R
47 T insertion between
nt 396 and 397
Frame shift R R R
48 T(515)RC Leu(172)RPro R ref. [2] R R
49 C(458)RT, C(474)RA Thr(153)RIle,
Asp(159)RGlu
NA S R
51 57–59, 62–65, 70–74 deleted Frame shift R R R
a, wild type sequence.
b, silent mutation, the amino acid sequence was not changed.
c, sequencing result is disordered.
d, sputum sample was not tested by the BACTEC MGIT 960 system.
S, PZA susceptible.
R, PZA resistant.
NA, not available.
ref. , reference that reported the mutation sites leading to PZA resistance.
doi:10.1371/journal.pone.0027654.t001
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Bacterial strains
M. tuberculosis strain M. tuberculosis H37Ra (PZA susceptible) and
M. bovis M. bovis BCG strain Tokyo (PZA resistant) have been
maintained in our laboratory. All the clinical isolates and the
sputum samples with positive smear for acid-fast bacilli (AFB) used
in this study were derived from the sputum of patients treated in
Wuhan Tuberculosis Control Center (Wuhan, China) and chosen
randomly. The M. tuberculosis isolate cells were collected from the
standard Lowenstein-Jensen media seeded with the sputum
samples. Before the susceptibility test, the isolates were stored at
a4 uC refrigerator. Written informed consent was obtained from
all participants. The study and the consent procedure were
approved by the Ethical and Scientific Committee of Wuhan
Tuberculosis Control Center and the Academic and Ethical
Committee of Wuhan Institute of Virology, Chinese Academy of
Sciences.
General procedure of the In-Vitro Synthesized
Pyrazinamidase method
As shown in Fig. 4, the main steps consisted of PCR
amplification of the pncA genes extracted from clinical samples,
in-vitro expression of the PCR products and determination of the
activities of the synthesized PZase. The total turnaround time
was less than 24 h. The detailed experimental conditions are
given in the supporting information sections (Method S1).
Briefly, tubercle bacilli were collected from L–J medium (for
isolates) or sputum specimens, and inactivated at 100uCf o r
10 min to obtain the DNA templates. Then, pncA gene fragments
were amplified by PCR with primers shown in Fig. 1 and Table
S1. After that, the amplified pncA DNA were concentrated and
used directly for in-vitro synthesis of PZase by RTS 100 Wheat
germ CECF kits (5 Prime Inc., Gaithersburg, USA). Finally, the
resulting lysates were used directly for PZase activity assay based
on the color developed due to the reaction of iron (II) with
Table 2. Comparison of the in-vitro synthesized PZase assay with BACTEC MGIT 960 and pncA sequencing.
N=51 BACTEC MGIT 960 pncA sequencing
Susceptible
(28)
Resistant
(23)
Wild type/silent
mutant (33) Mutants (16)
No
result
(2)
In-vitro PZase Susceptible (35) 27 8 33 2 0
In-vitro PZase Resistant (16) 1 15 0 14 2
Sensitivity 65% 88%
Specificity 96% 100%
doi:10.1371/journal.pone.0027654.t002
Figure 4. General procedure of the PCR-based in-vitro synthesized PZase assay. The in-vitro PZase assay consisted of four steps. (A)
Extraction of DNA from samples. (B) PCR amplification of the pncA gene. (C) In-vitro synthesis of PZase. (D) Assay of PZase activity. T7 P: T7 promoter.
59UTR: 59untranslated regulatory regions containing translational enhancer elements.
doi:10.1371/journal.pone.0027654.g004
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synthesized PZase. A sample was considered as resistant if its
synthesized PZase showed any reduction in activity/color
absorption compared with that of the PZase from M. tuberculosis
H37Ra, otherwise, as susceptible.
DNA sequencing
The PCR products (with primers F-5 and R-1) of the
pncA genes (GenBank accession number U59967) from the
isolates and the sputum samples were directly sequenced
using the sequencing primer 59-TAATACGACTCACTA-
TAG-39 by Invitrogen Inc. (Shanghai, China). The resulting
sequences were compared with the pncA sequence of M.
tuberculosis H37Ra to identify mutations associated with PZA
resistance.
Test PZA susceptibility by BACTEC MGIT 960
PZA susceptibility tests of the clinical isolates were performed
on a BACTEC MGIT 960 system using the PZA susceptibility
test kits (Becton Dickinson, Sparks, MD) according to the
manufacturer’s instructions. A PZA concentration of 100 mg/ml
(recommended breakpoint) was used.
Supporting Information
Figure S1 The sequencing peaks of the pncA gene of M.
tuberculosis isolates No 26 (A) and No 44 (B). The double peaks start
from position 223 for the isolate No 26 and position 315 for the
isolate No 44, respectively.
(TIF)
Table S1 Primer sequences used for amplification of the pncA
gene of M. tuberculosis.
(DOC)
Method S1 Detailed conditions for the In-Vitro Synthesized
Pyrazinamidase method.
(DOC)
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